Search Result
Results for "
Monomethyl
" in MedChemExpress (MCE) Product Catalog:
7
Biochemical Assay Reagents
7
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-103252S
-
-
-
- HY-103252
-
-
-
- HY-33048
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-1 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-N8931
-
Lithospermic acid Monomethyl ester
|
Akt
|
Neurological Disease
|
Monomethyl lithospermate activates the PI3K/AKT pathway, which plays a protective role in nerve injury. Monomethyl lithospermate can improve the survival ability of SHSY-5Y cells, inhibit the breakdown of mitochondrial membrane potential (MMOP) and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of rats with middle artery occlusion (MCAO) and improved nerve damage in rats with ischemic stroke (IS) .
|
-
-
- HY-103252S1
-
-
-
- HY-43146
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-3 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-43147
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-4 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-43149
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-5 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-49413
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-2 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78899
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-6 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78901
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-7 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78901A
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-8 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78903
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-9 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78903A
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-10 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78908
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-11 is an intermediate reactant in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78910
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-12 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78911
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-13 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-78913
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-14 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-79196
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-15 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-79198
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-16 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-79205
-
|
Others
|
Cancer
|
Monomethyl auristatin E intermediate-17 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-Y1097
-
2-(Methoxycarbonyl)benzoic acid
|
|
|
Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule .
|
-
-
- HY-N3247
-
|
Parasite
|
Others
|
Monomethyl kolavate is a Trypanosoma brucei GAPDH enzyme (TbGAPDH) inhibitor with theIC50 value of 2 µM .
|
-
-
- HY-15162G
-
MMAE; SGD-1010; Vedotin
|
Microtubule/Tubulin
Apoptosis
ADC Cytotoxin
|
Cancer
|
Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor .
|
-
-
- HY-Y1097S
-
2-(Methoxycarbonyl)benzoic acid-d4
|
Isotope-Labeled Compounds
|
Cancer
|
Monomethyl phthalate-d4 (2-(Methoxycarbonyl)benzoic acid-d4) is the deuterium labeled Monomethyl phthalate. Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule .
|
-
-
- HY-15162
-
MMAE; SGD-1010; Vedotin
|
Microtubule/Tubulin
ADC Cytotoxin
Apoptosis
|
Cancer
|
Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
|
-
-
- HY-79256
-
Monomethyl auristatin F methyl ester
|
ADC Cytotoxin
|
Cancer
|
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 -) cell lines, respectively.
|
-
-
- HY-15581
-
Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).
|
-
-
- HY-15162A
-
-
-
- HY-15581S
-
Demethyldolastatin 10-d8; Monomethylauristatin D-d8; Monomethyl Dolastatin 10-d8
|
ADC Cytotoxin
Microtubule/Tubulin
|
Cancer
|
MMAD-d8D is a deuterated form of MMAD, which is a microtubule disrupting agent.
|
-
-
- HY-135584
-
|
Estrogen Receptor/ERR
|
|
Raloxifene 6-Monomethyl Ether (Compound 7) is a Raloxifene derivative that inhibits estrogen receptor α. Raloxifene 4-Monomethyl Ether inhibits MCF-7 cells with an IC50 of 250 nM and a pIC50 of 6.6 .
|
-
-
- HY-135590
-
|
Estrogen Receptor/ERR
|
|
Raloxifene 4-Monomethyl Ether (Compound 37) is a Raloxifene derivative that inhibits estrogen receptor α. Raloxifene 4-Monomethyl Ether inhibits MCF-7 cells with an IC50 of 1 μM and a pIC50 of 6 .
|
-
-
- HY-144182S
-
-
-
- HY-N3754
-
|
Parasite
|
Infection
|
Dihydropinosylvin monomethyl ether is a natrual compound with nematicidal activity. Dihydropinosylvin monomethyl ether can inhibit pine wood nematodes infection .
|
-
-
- HY-N6904
-
|
Amyloid-β
|
Neurological Disease
Inflammation/Immunology
|
Crocetin monomethyl ester, isolated from Crocus sativus, possesses anti-inflammatory, neuroprotective and antioxidant activity . Crocetin monomethyl ester promotes clearance of amyloid-β by inducing autophagy via the STK11/LKB1-mediated AMPK pathway .
|
-
-
- HY-N3056
-
-
-
- HY-N3420
-
|
Others
|
Cancer
|
Koaburaside monomethyl ether is a phenolic glycoside that can be isolated from Averrhoa carambola L. .
|
-
-
- HY-W018365
-
|
PROTAC Linkers
|
Cancer
|
Tetraethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
-
- HY-120175
-
|
PROTAC Linkers
|
Cancer
|
Nonaethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
-
- HY-W042625
-
|
PROTAC Linkers
|
Cancer
|
Hexaethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
-
- HY-W042657
-
|
PROTAC Linkers
|
Cancer
|
Octaethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
-
- HY-W042713
-
|
PROTAC Linkers
|
Cancer
|
Pentaethylene glycol monomethyl ether is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
-
- HY-126492
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Vat-Cit-PAB-Monomethyl Dolastatin 10 is a agent-linker conjugate for ADC with potent antitumor activity by using Monomethyl Dolastatin 10 (a potent tubulin inhibitor), linked via the ADC linker Vat-Cit-PAB.
|
-
-
- HY-78899A
-
|
Others
|
Cancer
|
(4R,5S)-Monomethyl auristatin E intermediate-6 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
|
-
-
- HY-N7982
-
|
Others
|
Others
|
(+)-Pinoresinol monomethyl ether O-β-D-glucoside (Compound 6) is a natural product that can be isolated from the stems of Tinospora sinensis .
|
-
-
- HY-134990
-
|
Apoptosis
|
Cancer
|
Hematoporphyrin monomethyl ether, second generation of porphyrin-related photosensitizer, is characterized by its single form, high yield of singlet oxygen, high selectivity, and low toxicity, which has been widely used in the diagnosis and research of various tumors, including lung cancer, bladder cancer, and nevus flammeus and brain glioma .
|
-
-
- HY-W133953
-
Propylene glycol Monomethyl ether acetate
|
Biochemical Assay Reagents
|
Others
|
1-Methoxy-2-propyl acetate (Propylene glycol monomethyl ether acetate) is utilized as solvent, especially in the electronic-grade semiconductor industry .
|
-
-
- HY-P99956
-
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
|
-
-
- HY-141218
-
Decaethylene glycol Monomethyl ether
|
ADC Linker
PROTAC Linkers
|
Cancer
|
m-PEG10-alcohol (Decaethylene glycol monomethyl ether) is a non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . m-PEG10-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
-
- HY-100566
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
|
-
- HY-156712
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) and the cytotoxic agent Monomethyl auristatin E (MMAE). Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR .
|
-
- HY-W142140
-
N-Methylvaline
|
Amino Acid Derivatives
|
Others
|
N-Methyl-DL-valine is a valine derivant, is metabolized to cysteine, alanine, tyrosine, tryptophan, citric acid, and succinic acid in the sprout. N-Methyl-DL-valine involves in the modification of monomethyl auristatin F (MMAF), an anti-tubulin agent, makes it hydrophobic functionalization and increases cell permeability .
|
-
- HY-78931
-
|
ADC Linker
|
Cancer
|
Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-W013863
-
Alternariol Monomethyl ether
|
Antibiotic
Bacterial
|
Others
|
Djalonensone, isolated from the roots of Anthocleista djalonensis (Loganiaceae), is an important taxonomic marker of the plant species .
|
-
- HY-N0829
-
|
Others
|
Inflammation/Immunology
|
Shionone is the major triterpenoid isolated from Aster tataricus, has anti-tussive, anti-inflammatory activities . Shionone possesses a unique six-membered tetracyclic skeleton and 3-oxo-4-monomethyl structure .
|
-
- HY-78931G
-
|
ADC Linker
|
Cancer
|
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-78932
-
|
Others
|
Cancer
|
Dap-NE is an intermediate reagent in the synthesis of the ADC toxin Monomethyl auristatin E (HY-15162) .
|
-
- HY-78931C
-
|
Others
|
Cancer
|
(S,S,R,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-78931E
-
|
Others
|
Cancer
|
(R,S,R,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-78931F
-
|
Others
|
Cancer
|
(R,S,S,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-140485
-
|
PROTAC Linkers
|
Cancer
|
Acid-PEG5-mono-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
- HY-140486
-
|
PROTAC Linkers
|
Cancer
|
Acid-PEG6-mono-methyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
- HY-78931A
-
|
Others
|
Cancer
|
(R,S,S,R,S)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-78931B
-
|
Others
|
Cancer
|
(S,S,S,S,R)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-140484
-
|
PROTAC Linkers
|
Cancer
|
Acid-PEG3-mono-methyl ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
- HY-111811
-
|
Others
|
Inflammation/Immunology
|
Homomangiferin is mangiferin monomethyl ether. Homomangiferin has important medicinal properties and is widely used to relieve many symptoms, for example coughing and asthma .
|
-
- HY-W039197
-
|
PROTAC Linkers
|
Cancer
|
Acid-PEG4-mono-methyl ester is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs .
|
-
- HY-141860
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.
|
-
- HY-15741
-
-
- HY-78933
-
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC .
|
-
- HY-153428
-
-
- HY-109105
-
XP-23829; PPC-06
|
Others
|
Inflammation/Immunology
|
Tepilamide fumarate (XP-23829; PPC-06) is an oral fumaric acid ester, acts as a proagent of Monomethyl fumarate (HY-103252), and is used in the research of moderate to severe chronic plaque psoriasis .
|
-
- HY-157284
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs .
|
-
- HY-78738
-
|
ADC Linker
|
Cancer
|
MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
- HY-128711
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F) .
|
-
- HY-160702
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DMBA-SIL-Mal-MMAE is a cytotoxin-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked DMBA-SIL-Mal .
|
-
- HY-W127850
-
MMT
|
Biochemical Assay Reagents
|
Others
|
10,10'-Dimethyl-9,9'-biacridinium bismonomethyl Terephthalate (MMT) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-126681
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SC-VC-PAB-MMAE is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .
|
-
- HY-153976
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker .
|
-
- HY-15575
-
VcMMAE
Maximum Cited Publications
45 Publications Verification
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
|
-
- HY-126686
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate.
|
-
- HY-152916
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
mp-dLAE-PABC-MMAE is a agent-linker conjugate for ADC. mp-dLAE-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (HY-15162). mp-dLAE-PABC-MMAE can be used to synthesis antibody-drug conjugates (ADCs) .
|
-
- HY-P99593A
-
DMUC5754A (solution)
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .
|
-
- HY-P1108
-
|
CFTR
|
Others
|
Astressin 2B is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B antagonizes CRF2-mediated inhibition of gastric emptying .
|
-
- HY-P1108A
-
|
CFTR
|
Others
|
Astressin 2B TFA is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B TFA antagonizes CRF2-mediated inhibition of gastric emptying .
|
-
- HY-141601
-
ABBV-399
|
Antibody-Drug Conjugates (ADCs)
c-Met/HGFR
|
Cancer
|
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used in cancer research .
|
-
- HY-P99970
-
|
ADC Antibody
|
Others
|
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .
|
-
- HY-P99107A
-
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
Brentuximab vedotin solution is the solution form of Brentuximab vedotin (HY-P99107). Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE) .
|
-
- HY-P9985
-
RC48
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .
|
-
- HY-147286A
-
-
- HY-W142140A
-
N-Methylvaline hydrochloride
|
Others
|
Cancer
|
N-Methyl-DL-valine (N-Methylvaline) hydrochloride is a valine derivant, is metabolized to cysteine, alanine, tyrosine, tryptophan, citric acid, and succinic acid in the sprout. N-Methyl-DL-valine hydrochloride involves in the modification of monomethyl auristatin F (MMAF), an anti-tubulin agent, makes it hydrophobic functionalization and increases cell permeability .
|
-
- HY-P99205
-
|
ADC Antibody
|
Cancer
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
- HY-78738G
-
|
ADC Linker
|
Cancer
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
- HY-15575S
-
MC-Val-Cit-PAB-MMAE-d8; mc-vc-PAB-MMAE-d8
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
- HY-132253
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-152963
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF). Tisotumab vedotin consists of a fully human monoclonal antibody to tissue factor (TF-011) conjugated to Monomethyl Auristatin E (MMAE). Tisotumab vedotin has good antitumor activity and can be used in the research of advanced or metastatic solid tumors .
|
-
- HY-140697
-
mPEG-Hydroxy (MW5000); Polyethylene glycol Monomethyl ether (MW5000)
|
PROTAC Linkers
|
Cancer
|
m-PEG-OH (MW5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
- HY-140696
-
mPEG-Hydroxy (MW 2000); Polyethylene glycol Monomethyl ether (MW 2000)
|
PROTAC Linkers
|
Cancer
|
m-PEG-OH (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
- HY-140696C
-
mPEG-Hydroxy (MW 20000); Polyethylene glycol Monomethyl ether (MW 20000)
|
PROTAC Linkers
|
Cancer
|
m-PEG-OH (MW 20000) can be used as a macroinitiator to participate in the synthesis of amphiphilic block copolymers. Nanoscale micelles can be prepared by using amphiphilic block copolymers to deliver active drugs. Paclitaxel (HY-B0015), a hydrophobic anticancer agent encapsulated in micelles, has stronger activity in killing cancer cells than free Paclitaxel. And it preferentially accumulates in tumor tissue with only limited distribution in healthy organs.
|
-
- HY-140696D
-
mPEG-Hydroxy (MW 10000); Polyethylene glycol Monomethyl ether (MW 10000)
|
PROTAC Linkers
|
Cancer
|
m-PEG-OH (MW 10000) can be used as a macroinitiator to participate in the synthesis of amphiphilic block copolymers. Amphiphilic block copolymers can be used to prepare nanoscale micelles to deliver active drugs. Paclitaxel (HY-B0015), a hydrophobic anticancer agent encapsulated in micelles, has stronger activity in killing cancer cells than free Paclitaxel. And it preferentially accumulates in tumor tissue with only limited distribution in healthy organs.
|
-
- HY-140696E
-
mPEG-Hydroxy (MW 1000); Polyethylene glycol Monomethyl ether (MW 1000)
|
PROTAC Linkers
|
Cancer
|
m-PEG-OH (MW 1000) can be used as a macroinitiator to participate in the synthesis of amphiphilic block copolymers. Amphiphilic block copolymers can be used to prepare nanoscale micelles to deliver active drugs. Paclitaxel (HY-B0015), a hydrophobic anticancer agent encapsulated in micelles, has stronger cancer-killing activity than free Paclitaxel. And it accumulates preferentially in tumor tissues and has only limited distribution in healthy organs.
|
-
- HY-100375
-
ALKS 8700; BIIB098
|
|
|
Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF). Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS). Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity .
|
-
- HY-P99107
-
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
TNF Receptor
|
Cancer
|
Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma .
|
-
- HY-P4521
-
|
MMP
|
Others
|
Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt is a MMP12 substrate, and can be used to detect MMP12 enzyme activity .
|
-
- HY-P3066
-
d(CH2)5Tyr(Et)VAVP
|
Vasopressin Receptor
|
Metabolic Disease
|
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .
|
-
- HY-130161
-
|
ADC Linker
PROTAC Linkers
|
Cancer
|
m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907). m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency . m-PEG4-Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-126690
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-P10272
-
PTG-300
|
Ferroportin
|
Others
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-111012
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-W190943
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
Cat. No. |
Product Name |
Type |
-
- HY-15162G
-
MMAE (GMP); SGD-1010 (GMP); Vedotin (GMP)
|
Fluorescent Dye
|
Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor .
|
-
- HY-78931G
-
|
Fluorescent Dye
|
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-78738G
-
|
Fluorescent Dye
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
Cat. No. |
Product Name |
Type |
-
- HY-W133953
-
Propylene glycol Monomethyl ether acetate
|
Biochemical Assay Reagents
|
1-Methoxy-2-propyl acetate (Propylene glycol monomethyl ether acetate) is utilized as solvent, especially in the electronic-grade semiconductor industry .
|
-
- HY-15162G
-
MMAE (GMP); SGD-1010 (GMP); Vedotin (GMP)
|
Biochemical Assay Reagents
|
Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor .
|
-
- HY-78931G
-
|
Biochemical Assay Reagents
|
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
|
-
- HY-78738G
-
|
Biochemical Assay Reagents
|
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
|
-
- HY-140696C
-
mPEG-Hydroxy (MW 20000); Polyethylene glycol Monomethyl ether (MW 20000)
|
Drug Delivery
|
m-PEG-OH (MW 20000) can be used as a macroinitiator to participate in the synthesis of amphiphilic block copolymers. Nanoscale micelles can be prepared by using amphiphilic block copolymers to deliver active drugs. Paclitaxel (HY-B0015), a hydrophobic anticancer agent encapsulated in micelles, has stronger activity in killing cancer cells than free Paclitaxel. And it preferentially accumulates in tumor tissue with only limited distribution in healthy organs.
|
-
- HY-140696D
-
mPEG-Hydroxy (MW 10000); Polyethylene glycol Monomethyl ether (MW 10000)
|
Drug Delivery
|
m-PEG-OH (MW 10000) can be used as a macroinitiator to participate in the synthesis of amphiphilic block copolymers. Amphiphilic block copolymers can be used to prepare nanoscale micelles to deliver active drugs. Paclitaxel (HY-B0015), a hydrophobic anticancer agent encapsulated in micelles, has stronger activity in killing cancer cells than free Paclitaxel. And it preferentially accumulates in tumor tissue with only limited distribution in healthy organs.
|
-
- HY-140696E
-
mPEG-Hydroxy (MW 1000); Polyethylene glycol Monomethyl ether (MW 1000)
|
Drug Delivery
|
m-PEG-OH (MW 1000) can be used as a macroinitiator to participate in the synthesis of amphiphilic block copolymers. Amphiphilic block copolymers can be used to prepare nanoscale micelles to deliver active drugs. Paclitaxel (HY-B0015), a hydrophobic anticancer agent encapsulated in micelles, has stronger cancer-killing activity than free Paclitaxel. And it accumulates preferentially in tumor tissues and has only limited distribution in healthy organs.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1108A
-
|
CFTR
|
Others
|
Astressin 2B TFA is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B TFA antagonizes CRF2-mediated inhibition of gastric emptying .
|
-
- HY-W142140
-
N-Methylvaline
|
Amino Acid Derivatives
|
Others
|
N-Methyl-DL-valine is a valine derivant, is metabolized to cysteine, alanine, tyrosine, tryptophan, citric acid, and succinic acid in the sprout. N-Methyl-DL-valine involves in the modification of monomethyl auristatin F (MMAF), an anti-tubulin agent, makes it hydrophobic functionalization and increases cell permeability .
|
-
- HY-P4756
-
|
Peptides
|
Others
|
N-(2-Carbamoyl-ethyl)-Val-Leu-anilide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P1108
-
|
CFTR
|
Others
|
Astressin 2B is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B antagonizes CRF2-mediated inhibition of gastric emptying .
|
-
- HY-P2592
-
|
Peptides
|
Others
|
Ro 23-7014 is an appetite suppressant. Ro 23-7014 is an analog of cholecystokinin (CCK-7) .
|
-
- HY-P4521
-
|
MMP
|
Others
|
Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt is a MMP12 substrate, and can be used to detect MMP12 enzyme activity .
|
-
- HY-P3066
-
d(CH2)5Tyr(Et)VAVP
|
Vasopressin Receptor
|
Metabolic Disease
|
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .
|
-
- HY-P10272
-
PTG-300
|
Ferroportin
|
Others
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99956
-
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
|
-
- HY-P99970
-
|
ADC Antibody
|
Others
|
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .
|
-
- HY-P99205
-
|
ADC Antibody
|
Cancer
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
- HY-132253
-
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-P99593A
-
DMUC5754A (solution)
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P81056
-
MMAE; Monomethyl auristatin E; Monomethylauristatin E; Monomethylauristatin norephedrine; Toxin MMAE; MMAE toxin
|
ELISA;
|
Species independent |
MMAE Antibody (YA899) is an unconjugated, rabbit-derived, anti-MMAE (YA899) monoclonal antibody. MMAE Antibody (YA899) can be used for: ELISA, Sandwich ELISA, Competitive ELISA expriments in background without labeling.
|
-
- HY-P81057
-
Monomethylauristatin F, Monomethyl Auristatin F, 745017-94-1
|
ELISA; Sandwich ELISA; Competitive ELISA
|
|
MMAF Antibody (YA900) is an unconjugated, mouse-derived, anti-MMAF (YA900) monoclonal antibody. MMAF Antibody (YA900) can be used for: ELISA, Sandwich ELISA, Competitive ELISA expriments in background without labeling.
|
-
- HY-P81287A
-
H3K14me; H3.4; H3/g; H3FT; H3t
|
WB, ICC/IF
|
Human, Mouse |
-
- HY-P81287
-
H3K79me; H3 histone; HIST1H3A; Histone cluster 1; H3a
|
WB, IHC-P
|
Human, Mouse, Rat |
-
- HY-P83301
-
H4K16me; H4; H4/n; H4F2; H4FN; FO108; HIST2H4
|
WB, ICC/IF
|
Human, Mouse |
Cat. No. |
Product Name |
|
Classification |
-
- HY-126690
-
|
|
DBCO
|
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-111012
-
|
|
DBCO
|
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-W190943
-
|
|
Azide
|
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: